報價延遲最少15分鐘:2025/05/31 11:56 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.63 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
2.88/-1.12
|
|
企業價值
38.02M
|
| 資產負債 |
|
每股賬面淨值
0.13
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
843.00K
|
|
每股收益
0.02
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/05/31 11:56 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib and plogosertib. |